Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Reports First Quarter 2018 Financial Results
-- Introduced XmAb® IL15 Bispecific Antibody Platform and Presented Preclinical Data on XmAb®24306 at American Association for Cancer Research (AACR) Annual Meeting -- - Completed Public Offering, Raising $245.5M and Extending Cash Runway into 2023 - -- Expect to Initiate Phase 3 Trial of XmAb®5871
View HTML
Toggle Summary Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference
MONROVIA, Calif. , May 2, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,
View HTML
Toggle Summary Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018
MONROVIA, Calif. , April 30, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release first quarter
View HTML
Toggle Summary Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
MONROVIA, Calif. , April 18, 2018 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced preclinical data on XmAb24306, an
View HTML
Toggle Summary Xencor to Present at 17th Annual Needham Healthcare Conference
MONROVIA, Calif. , March 21, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,
View HTML
Toggle Summary Xencor Announces Pricing of Public Offering of Common Stock
MONROVIA, Calif. , March 20, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of an underwritten public offering of 7,300,000 shares of its common stock at a price to the public of $31.00 per share. All of the shares are being sold by Xencor .
View HTML
Toggle Summary Xencor, Inc. Announces Proposed Public Offering of Common Stock
MONROVIA, Calif. , March 19, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option
View HTML
Toggle Summary Xencor Reports Fourth Quarter and Full Year 2017 Financial Results
-- Broadening Tumor Microenvironment (TME)-Targeting Bispecific Pipeline with XmAb®24306, Targeting IL-15/ILRa for Multiple Oncology Indications -- -- Expect to Initiate Phase 3 Trial of XmAb®5871 in IgG4-Related Disease (IgG4-RD) in 2H18 -- -- Expect to Announce Initial Data from Phase 2 Trial of
View HTML
Toggle Summary Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors
MONROVIA, Calif. , Feb. 22, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been
View HTML
Toggle Summary Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018
MONROVIA, Calif. , Feb. 20, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and
View HTML
Xencor © Copyright 2018